Abiomed has reported second quarter revenue of $132.8 million, a 29 percent increase from the same period last year. Net income was reported at $24.5 million compared to $8.9 million for the prior year period.
Most of the growth is tied to worldwide revenue from the Impella heart pumps, which are used to provide circulatory support for heart failure patients and heart attack patients in cardiogenic shock. The Impella pumps generated $127.4 million in total revenue in the quarter, including a record $113.6 million in the U.S., where patient usage grew by 33 percent.
"This quarter, we set new records for supporting patients in the U.S. and Germany and we continue to observe improved clinical outcomes with our education and training initiatives," Michael R. Minogue, chairman, president and CEO of Abiomed, said in a statement. "I am proud of the team's ability to consistently adapt and execute as we transform the standard of care and build the field of heart recovery."
In a separate press release issued Oct. 26, the company announced its first patient in Japan had been treated with an Impella heart pump.
Daniel joined TriMed’s Chicago editorial team in 2017 as a Cardiovascular Business writer. He previously worked as a writer for daily newspapers in North Dakota and Indiana.